News
The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...
The Food and Drug Administration has required Pfizer and Moderna to expand the warning labels on their mRNA COVID-19 vaccines ...
1d
WGAU Radio on MSNFDA expands warning on rare heart risk linked to Pfizer and Moderna COVID vaccinesThe updated guidance highlights myocarditis and pericarditis, two types of heart inflammation, as possible adverse events ...
2d
Stocktwits on MSNModerna, Pfizer, Novavax Draw Bearish Buzz Ahead Of CDC Panel With Vaccine SkepticsRetail investor chatter around vaccine makers Novavax, Moderna, and Pfizer rose on Wednesday, ahead of a closely watched CDC ...
1don MSN
The FDA has issued warnings regarding potential cardiac risks, specifically myocarditis and pericarditis, associated with the ...
Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s skepticism of mRNA vaccines has cost the company dearly.
14d
Pharmaceutical Technology on MSNModerna’s mRNA RSV vaccine wins expanded FDA approval for younger adultsThe label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.
The strange clotting problem has caused nine confirmed deaths after J&J vaccinations — while the Pfizer and Moderna vaccines don’t come with that risk and also appear to be more effective ...
Cambridge, Massachusetts-based Alnylam first sued Moderna and Pfizer for patent infringement in 2022 for allegedly using its lipid nanoparticle (LNP) technology in their vaccines to deliver ...
Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services terminated a contract with drugmaker Moderna to develop an mRNA bird ...
Moderna's mRNA-based flu vaccine funding is cancelled by the Department of Health and Human Services, ... the technology that Moderna and Pfizer used to develop their COVID-19 vaccines. ...
Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results